Literature DB >> 9687397

Activities of three quinolones, alone and in combination with extended-spectrum cephalosporins or gentamicin, against Stenotrophomonas maltophilia.

M A Visalli1, M R Jacobs, P C Appelbaum.   

Abstract

The present study examined the activities of trovafloxacin, levofloxacin, and ciprofloxacin, alone and in combination with cefoperazone, ceftazidime, cefpirome, and gentamicin, against 100 strains of Stenotrophomonas maltophilia by the MIC determination method and by synergy testing of the combinations by the time-kill and checkerboard titration methods for 20 strains. The respective MICs at which 50% and 90% of isolates were inhibited for the drugs used alone were as follows: trovafloxacin, 0.5 and 2.0 microg/ml; levofloxacin, 2.0 and 4.0 microg/ml; ciprofloxacin, 4.0 and 16.0 microg/ml; cefoperazone, >128.0 and >128.0 microg/ml; ceftazidime, 32.0 and >128.0 microg/ml; cefpirome, >128.0 and >128.0 microg/ml; and gentamicin, 128.0 and >128.0 microg/ml. Synergistic fractional inhibitory concentration indices (</=0.5) were found for >/=50% of strains for trovafloxacin-cefoperazone, trovafloxacin-ceftazidime, levofloxacin-cefoperazone, levofloxacin-ceftazidime, ciprofloxacin-cefoperazone, and ciprofloxacin-ceftazidime, with other combinations affecting fewer strains. For 20 strains tested by the checkerboard titration and time-kill methods, synergy (>/=100-fold drop in count compared to the count achieved with the more active compound) was more pronounced after 12 h due to regrowth after 24 h. At 12 h, trovafloxacin at 0.004 to 0.5 microg/ml showed synergy with cefoperazone for 90% of strains, with ceftazidime for 95% of strains with cefpirome for 95% of strains, and with gentamicin for 65% of strains. Levofloxacin at 0.03 to 0.5 microg/ml and ciprofloxacin at 0.5 to 2.0 microg/ml showed synergy with cefoperazone for 80% of strains, with ceftazidime for 90 and 85% of strains, respectively, with cefpirome for 85 and 75% of strains, respectively, and with gentamicin for 65 and 75% of strains, respectively. Time-kill assays were more discriminatory than checkerboard titration assays in demonstrating synergy for all combinations.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9687397      PMCID: PMC105723     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  16 in total

Review 1.  Classification of beta-lactamases: groups 2c, 2d, 2e, 3, and 4.

Authors:  K Bush
Journal:  Antimicrob Agents Chemother       Date:  1989-03       Impact factor: 5.191

2.  Nosocomial infections due to Xanthomonas maltophilia (Pseudomonas maltophilia) in patients with cancer.

Authors:  N Khardori; L Elting; E Wong; B Schable; G P Bodey
Journal:  Rev Infect Dis       Date:  1990 Nov-Dec

3.  In vitro susceptibility of Xanthomonas (Pseudomonas) maltophilia to newer antimicrobial agents.

Authors:  N Khardori; A Reuben; B Rosenbaum; K Rolston; G P Bodey
Journal:  Antimicrob Agents Chemother       Date:  1990-08       Impact factor: 5.191

4.  Comparative activity of trovafloxacin, alone and in combination with other agents, against gram-negative nonfermentative rods.

Authors:  M A Visalli; S Bajaksouzian; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

5.  Purification and properties of an inducible cephalosporinase from Pseudomonas maltophilia GN12873.

Authors:  Y Saino; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

6.  Purification and properties of inducible penicillin beta-lactamase isolated from Pseudomonas maltophilia.

Authors:  Y Saino; F Kobayashi; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1982-10       Impact factor: 5.191

7.  Antibiotic susceptibility and outer membrane proteins of clinical Xanthomonas maltophilia isolates.

Authors:  W Cullmann
Journal:  Chemotherapy       Date:  1991       Impact factor: 2.544

8.  Infections caused by Pseudomonas maltophilia. Expanding clinical spectrum.

Authors:  R R Muder; V L Yu; J S Dummer; C Vinson; R M Lumish
Journal:  Arch Intern Med       Date:  1987-09

9.  Associated mortality and clinical characteristics of nosocomial Pseudomonas maltophilia in a university hospital.

Authors:  A J Morrison; K K Hoffmann; R P Wenzel
Journal:  J Clin Microbiol       Date:  1986-07       Impact factor: 5.948

10.  Association of Pseudomonas maltophilia with malignant lesions.

Authors:  T Nagai
Journal:  J Clin Microbiol       Date:  1984-11       Impact factor: 5.948

View more
  9 in total

1.  Activities of clinafloxacin, alone and in combination with other compounds, against 45 gram-positive and -negative organisms for which clinafloxacin MICs are high.

Authors:  C L Clark; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1999-09       Impact factor: 5.191

2.  Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii.

Authors:  Glenn A Pankuch; Gengrong Lin; Harald Seifert; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2007-10-29       Impact factor: 5.191

Review 3.  A critical review of the fluoroquinolones: focus on respiratory infections.

Authors:  George G Zhanel; Kelly Ennis; Lavern Vercaigne; Andrew Walkty; Alfred S Gin; John Embil; Heather Smith; Daryl J Hoban
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 4.  Antimicrobial therapy for Stenotrophomonas maltophilia infections.

Authors:  A C Nicodemo; J I Garcia Paez
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-04       Impact factor: 3.267

5.  Synergistic activities of gatifloxacin in combination with other antimicrobial agents against Pseudomonas aeruginosa and related species.

Authors:  E Gradelski; L Valera; D Bonner; J Fung-Tomc
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

6.  Levofloxacin and ciprofloxacin in vitro activities against 4,003 clinical bacterial isolates collected in 24 Italian laboratories.

Authors:  Giovanni Pietro Gesu; Federico Marchetti; Laura Piccoli; Annalisa Cavallero
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

7.  Comparative in vitro activities of meropenem, imipenem, temocillin, piperacillin, and ceftazidime in combination with tobramycin, rifampin, or ciprofloxacin against Burkholderia cepacia isolates from patients with cystic fibrosis.

Authors:  S Bonacorsi; F Fitoussi; S Lhopital; E Bingen
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191

8.  Pharmacodynamic Interaction of Quercus infectoria Galls Extract in Combination with Vancomycin against MRSA Using Microdilution Checkerboard and Time-Kill Assay.

Authors:  Dayang Fredalina Basri; Radhiah Khairon
Journal:  Evid Based Complement Alternat Med       Date:  2012-07-31       Impact factor: 2.629

Review 9.  Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options.

Authors:  Ya-Ting Chang; Chun-Yu Lin; Yen-Hsu Chen; Po-Ren Hsueh
Journal:  Front Microbiol       Date:  2015-09-02       Impact factor: 5.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.